Eli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights to Tyvyt, their PD-1 inhibitor, which some analysts think may be launched at a ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Eli Lilly) up to 24 months before pregnancy had a 45% lower risk for cesarean delivery compared with those who received a prescription for a GLP-1 receptor agonist (OR = 0.55; 95% CI, 0.37-0.83).

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

and it has a PD-1 agonist called MB151 in late preclinical development. Other companies are working in this areas, notably Eli Lilly which has a BTLA4 agonist called LY3361237 in phase 2 for ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 ...